# Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma

> **NCT00411086** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Sargramostim (GM-CSF)

## Key facts

- **NCT ID:** NCT00411086
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411086, "Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00411086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*